Genotype-guided diagnostic reassessment after exome sequencing in neuromuscular disorders: experiences with a two-step approach

M. Krenn, M. Tomschik, J. Rath, H. Cetin, A. Grisold, G. Zulehner, I. Milenkovic, E. Stogmann, A. Zimprich, T. M. Strom, T. Meitinger, M. Wagner, F. Zimprich

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background and purpose: Next-generation sequencing has greatly improved the diagnostic success rates for genetic neuromuscular disorders (NMDs). Nevertheless, most patients still remain undiagnosed, and there is a need to maximize the diagnostic yield. Methods: A retrospective study was conducted on 72 patients with NMDs who underwent exome sequencing (ES), partly followed by genotype-guided diagnostic reassessment and secondary investigations. The diagnostic yields that would have been achieved by appropriately chosen narrow and comprehensive gene panels were also analysed. Results: The initial diagnostic yield of ES was 30.6% (n = 22/72 patients). In an additional 15.3% of patients (n = 11/72) ES results were of unknown clinical significance. After genotype-guided diagnostic reassessment and complementary investigations, the yield was increased to 37.5% (n = 27/72). Compared to ES, targeted gene panels (<25 kilobases) reached a diagnostic yield of 22.2% (n = 16/72), whereas comprehensive gene panels achieved 34.7% (n = 25/72). Conclusion: Exome sequencing allows the detection of pathogenic variants missed by (narrowly) targeted gene panel approaches. Diagnostic reassessment after genetic testing further enhances the diagnostic outcomes for NMDs.

Original languageEnglish
Pages (from-to)51-61
Number of pages11
JournalEuropean Journal of Neurology
Volume27
Issue number1
DOIs
StatePublished - 1 Jan 2020

Keywords

  • diagnostic reassessment
  • diagnostic yield
  • exome sequencing
  • gene panels
  • neuromuscular disorders
  • next-generation sequencing

Fingerprint

Dive into the research topics of 'Genotype-guided diagnostic reassessment after exome sequencing in neuromuscular disorders: experiences with a two-step approach'. Together they form a unique fingerprint.

Cite this